|
Phenotypic Information (metabolism pathway, cancer, disease, phenome) | |
Gene-Gene Network Information: Co-Expression Network, Interacting Genes & KEGG | |
Gene Summary for ADRA2A |
Basic gene info. | Gene symbol | ADRA2A |
Gene name | adrenoceptor alpha 2A | |
Synonyms | ADRA2|ADRA2R|ADRAR|ALPHA2AAR|ZNF32 | |
Cytomap | UCSC genome browser: 10q25.2 | |
Genomic location | chr10 :112836789-112840662 | |
Type of gene | protein-coding | |
RefGenes | NM_000681.3, | |
Ensembl id | ENSG00000150594 | |
Description | adrenergic, alpha-2A-, receptoralpha-2 adrenergic receptor subtype C10alpha-2-adrenergic receptor, platelet typealpha-2A adrenergic receptoralpha-2A adrenoceptoralpha-2A adrenoreceptoralpha-2AAR subtype C10 | |
Modification date | 20141207 | |
dbXrefs | MIM : 104210 | |
HGNC : HGNC | ||
Ensembl : ENSG00000150594 | ||
HPRD : 00078 | ||
Vega : OTTHUMG00000019050 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_ADRA2A | |
BioGPS: 150 | ||
Gene Expression Atlas: ENSG00000150594 | ||
The Human Protein Atlas: ENSG00000150594 | ||
Pathway | NCI Pathway Interaction Database: ADRA2A | |
KEGG: ADRA2A | ||
REACTOME: ADRA2A | ||
ConsensusPathDB | ||
Pathway Commons: ADRA2A | ||
Metabolism | MetaCyc: ADRA2A | |
HUMANCyc: ADRA2A | ||
Regulation | Ensembl's Regulation: ENSG00000150594 | |
miRBase: chr10 :112,836,789-112,840,662 | ||
TargetScan: NM_000681 | ||
cisRED: ENSG00000150594 | ||
Context | iHOP: ADRA2A | |
cancer metabolism search in PubMed: ADRA2A | ||
UCL Cancer Institute: ADRA2A | ||
Assigned class in ccmGDB | C |
Top |
Phenotypic Information for ADRA2A(metabolism pathway, cancer, disease, phenome) |
Cancer Description | |
Cancer | CGAP: ADRA2A |
Familial Cancer Database: ADRA2A |
* This gene is included in those cancer gene databases. |
Oncogene 1 | Significant driver gene in |
cf) number; DB name 1 Oncogene; http://nar.oxfordjournals.org/content/35/suppl_1/D721.long, 2 Tumor Suppressor gene; https://bioinfo.uth.edu/TSGene/, 3 Cancer Gene Census; http://www.nature.com/nrc/journal/v4/n3/abs/nrc1299.html, 4 CancerGenes; http://nar.oxfordjournals.org/content/35/suppl_1/D721.long, 5 Network of Cancer Gene; http://ncg.kcl.ac.uk/index.php, 1Therapeutic Vulnerabilities in Cancer; http://cbio.mskcc.org/cancergenomics/statius/ |
Metabolic Pathway Description | |
REACTOME_INTEGRATION_OF_ENERGY_METABOLISM |
Others | |
OMIM | |
Orphanet | |
Disease | KEGG Disease: ADRA2A |
MedGen: ADRA2A (Human Medical Genetics with Condition) | |
ClinVar: ADRA2A | |
Phenotype | MGI: ADRA2A (International Mouse Phenotyping Consortium) |
PhenomicDB: ADRA2A |
Mutations for ADRA2A |
* Under tables are showing count per each tissue to give us broad intuition about tissue specific mutation patterns.You can go to the detailed page for each mutation database's web site. |
Structural Variants in COSMIC: go to COSMIC mutation histogram |
There's no structural variation information in COSMIC data for this gene. |
Related fusion transcripts : go to Chitars2.0 |
* From mRNA Sanger sequences, Chitars2.0 arranged chimeric transcripts. This table shows ADRA2A related fusion information. |
ID | Head Gene | Tail Gene | Accession | Gene_a | qStart_a | qEnd_a | Chromosome_a | tStart_a | tEnd_a | Gene_a | qStart_a | qEnd_a | Chromosome_a | tStart_a | tEnd_a |
Other DBs for Structural Variants |
Top |
Copy Number Variations in COSMIC: go to COSMIC mutation CNV/Expr |
There's no copy number variation information in COSMIC data for this gene. |
Top |
SNV Counts per Each Loci in COSMIC data: go to COSMIC point mutation |
|
Top |
Somatic Mutation Counts per Tissue in COSMIC data |
Stat. for Non-Synonymous SNVs (# total SNVs=34) | (# total SNVs=15) |
(# total SNVs=0) | (# total SNVs=2) |
Top |
Top 10 SNVs Having the Most Samples in COSMIC data |
* When you move the cursor on each content, you can see more deailed mutation information on the Tooltip. Those are primary_site,primary_histology,mutation(aa),pubmedID. |
GRCh37 position | Mutation(aa) | Unique sampleID count |
chr10:112838344-112838344 | p.Q182L | 2 |
chr10:112838845-112838845 | p.P349L | 1 |
chr10:112839055-112839055 | p.S419N | 1 |
chr10:112838147-112838147 | p.F116L | 1 |
chr10:112838931-112838931 | p.V378L | 1 |
chr10:112838248-112838248 | p.I150T | 1 |
chr10:112838975-112838975 | p.F392L | 1 |
chr10:112838854-112838854 | p.E352G | 1 |
chr10:112839059-112839059 | p.S420S | 1 |
chr10:112838169-112838169 | p.L124M | 1 |
Top |
SNV Counts per Each Loci in TCGA data |
|
Point Mutation/ Tissue ID | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 |
# sample | 2 |   | 2 | 5 |   |   | 1 |   |   |   |   | 6 |   |   | 1 | 1 | 2 | 6 |   | 10 |
# mutation | 2 |   | 3 | 5 |   |   | 1 |   |   |   |   | 6 |   |   | 1 | 1 | 3 | 6 |   | 10 |
nonsynonymous SNV |   |   |   | 3 |   |   |   |   |   |   |   | 2 |   |   | 1 | 1 | 2 | 4 |   | 8 |
synonymous SNV | 2 |   | 3 | 2 |   |   | 1 |   |   |   |   | 4 |   |   |   |   | 1 | 2 |   | 2 |
cf) Tissue ID; Tissue type (1; BLCA[Bladder Urothelial Carcinoma], 2; BRCA[Breast invasive carcinoma], 3; CESC[Cervical squamous cell carcinoma and endocervical adenocarcinoma], 4; COAD[Colon adenocarcinoma], 5; GBM[Glioblastoma multiforme], 6; Glioma Low Grade, 7; HNSC[Head and Neck squamous cell carcinoma], 8; KICH[Kidney Chromophobe], 9; KIRC[Kidney renal clear cell carcinoma], 10; KIRP[Kidney renal papillary cell carcinoma], 11; LAML[Acute Myeloid Leukemia], 12; LUAD[Lung adenocarcinoma], 13; LUSC[Lung squamous cell carcinoma], 14; OV[Ovarian serous cystadenocarcinoma ], 15; PAAD[Pancreatic adenocarcinoma], 16; PRAD[Prostate adenocarcinoma], 17; SKCM[Skin Cutaneous Melanoma], 18:STAD[Stomach adenocarcinoma], 19:THCA[Thyroid carcinoma], 20:UCEC[Uterine Corpus Endometrial Carcinoma]) |
Top |
Top 10 SNVs Having the Most Samples in TCGA data |
* We represented just top 10 SNVs. When you move the cursor on each content, you can see more deailed mutation information on the Tooltip. Those are primary_site, primary_histology, mutation(aa), pubmedID. |
Genomic Position | Mutation(aa) | Unique sampleID count |
chr10:112838875 | p.A374V | 2 |
chr10:112838922 | p.I150T | 1 |
chr10:112838169 | p.V390L | 1 |
chr10:112838286 | p.E155E | 1 |
chr10:112838931 | p.V393L | 1 |
chr10:112838174 | p.V69I | 1 |
chr10:112838297 | p.R163H | 1 |
chr10:112837959 | p.Y409H | 1 |
chr10:112838979 | p.V73M | 1 |
chr10:112838175 | p.I165T | 1 |
Other DBs for Point Mutations |
Copy Number for ADRA2A in TCGA |
* Copy number data were extracted from TCGA using R package TCGA-Assembler. The URLs of all public data files on TCGA DCC data server were gathered on Jan-05-2015. Function ProcessCNAData in TCGA-Assembler package was used to obtain gene-level copy number value which is calculated as the average copy number of the genomic region of a gene. |
cf) Tissue ID[Tissue type]: BLCA[Bladder Urothelial Carcinoma], BRCA[Breast invasive carcinoma], CESC[Cervical squamous cell carcinoma and endocervical adenocarcinoma], COAD[Colon adenocarcinoma], GBM[Glioblastoma multiforme], Glioma Low Grade, HNSC[Head and Neck squamous cell carcinoma], KICH[Kidney Chromophobe], KIRC[Kidney renal clear cell carcinoma], KIRP[Kidney renal papillary cell carcinoma], LAML[Acute Myeloid Leukemia], LUAD[Lung adenocarcinoma], LUSC[Lung squamous cell carcinoma], OV[Ovarian serous cystadenocarcinoma ], PAAD[Pancreatic adenocarcinoma], PRAD[Prostate adenocarcinoma], SKCM[Skin Cutaneous Melanoma], STAD[Stomach adenocarcinoma], THCA[Thyroid carcinoma], UCEC[Uterine Corpus Endometrial Carcinoma] |
Top |
Gene Expression for ADRA2A |
Gene Expression in Cancer Cell-lines (CCLE) |
* CCLE gene expression data were extracted from CCLE_Expression_Entrez_2012-10-18.res: Gene-centric RMA-normalized mRNA expression data. |
Differential Gene Expression in Primary Tumors (TCGA) |
* Normalized gene expression data of RNASeqV2 was extracted from TCGA using R package TCGA-Assembler. The URLs of all public data files on TCGA DCC data server were gathered at Jan-05-2015. Only eight cancer types have enough normal control samples for differential expression analysis. (t test, adjusted p<0.05 (using Benjamini-Hochberg FDR)) |
Top |
CNV vs Gene Expression Plot |
* This plots show the correlation between CNV and gene expression. |
Top |
Gene-Gene Network Information |
Co-Expressed gene's network Plot |
* Co-Expression network figures were drawn using R package igraph. Only the top 20 genes with the highest correlations were shown. Red circle: input gene, orange circle: cell metabolism gene, sky circle: other gene |
ADRA2A,WBP1L,DHX29,EBF3,GDF10,GHR,GLUD1, HIGD1C,HSPA12B,HTR1B,IL6ST,KLHDC1,KLK12,KLK14, KRTAP6-2,NRXN3,RAI2,RANBP3L,ZNF224,ZNF226,ZNF230 | ADRA2A,ASAH1,BTD,FAM213A,C19orf12,C2CD2,DHDDS, EPAS1,FZD4,GNS,HRASLS5,LOC158376,MGST1,MMD, PALM2-AKAP2,PYGL,SAR1A,SEPT11,SORBS1,TK2,VKORC1L1 | ||||
ACY3,ADH6,ADRA2A,B3GALT5,BCAR4,BTNL8,LINC00483, CA9,CES2,CLTC,COX8C,DNM2,DOK4,KIAA1211, LIMA1,LIPC,MUC17,OSTalpha,SLC41A2,SULT1C2,ABHD11-AS1 | ACOX1,ADRA2A,AGFG2,APLP2,ARF3,RHOV___CHP1,CLIP2, EHHADH,FUT3,HSD17B2,LOC25845,NDRG1,NETO2,OPN3, RTN3,SFXN5,SLC16A1,SLC20A1,SLC9A3,STK38,WSCD1 |
Co-Expressed gene's Protein-protein interaction Network Plot |
* Co-Expression network figures were drawn using R package igraph. Only the top 20 genes with the highest correlations were shown. Red circle: input gene, orange circle: cell metabolism gene, sky circle: other gene |
Top |
Interacting Genes (from Pathway Commons) |
Top |
Pharmacological Information for ADRA2A |
Cross-referenced pharmacological DB IDs from Uniprot |
DB Category | DB Name | DB's ID and Url link |
Drug-Gene Interaction Network |
* Gene Centered Interaction Network. |
* Drug Centered Interaction Network. |
DrugBank ID | Target Name | Drug Groups | Generic Name | Drug Centered Network | Drug Structure |
DB00217 | adrenoceptor alpha 2A | approved | Bethanidine | ||
DB00246 | adrenoceptor alpha 2A | approved | Ziprasidone | ||
DB00248 | adrenoceptor alpha 2A | approved | Cabergoline | ||
DB00268 | adrenoceptor alpha 2A | approved; investigational | Ropinirole | ||
DB00320 | adrenoceptor alpha 2A | approved | Dihydroergotamine | ||
DB00321 | adrenoceptor alpha 2A | approved | Amitriptyline | ||
DB00334 | adrenoceptor alpha 2A | approved; investigational | Olanzapine | ||
DB00363 | adrenoceptor alpha 2A | approved | Clozapine | ||
DB00368 | adrenoceptor alpha 2A | approved | Norepinephrine | ||
DB00370 | adrenoceptor alpha 2A | approved | Mirtazapine | ||
DB00397 | adrenoceptor alpha 2A | approved; withdrawn | Phenylpropanolamine | ||
DB00413 | adrenoceptor alpha 2A | approved; investigational | Pramipexole | ||
DB00449 | adrenoceptor alpha 2A | approved | Dipivefrin | ||
DB00484 | adrenoceptor alpha 2A | approved | Brimonidine | ||
DB00543 | adrenoceptor alpha 2A | approved | Amoxapine | ||
DB00575 | adrenoceptor alpha 2A | approved | Clonidine | ||
DB00589 | adrenoceptor alpha 2A | approved | Lisuride | ||
DB00629 | adrenoceptor alpha 2A | approved | Guanabenz | ||
DB00633 | adrenoceptor alpha 2A | approved | Dexmedetomidine | ||
DB00656 | adrenoceptor alpha 2A | approved; investigational | Trazodone | ||
DB00668 | adrenoceptor alpha 2A | approved | Epinephrine | ||
DB00692 | adrenoceptor alpha 2A | approved | Phentolamine | ||
DB00696 | adrenoceptor alpha 2A | approved | Ergotamine | ||
DB00697 | adrenoceptor alpha 2A | approved | Tizanidine | ||
DB00714 | adrenoceptor alpha 2A | approved; investigational | Apomorphine | ||
DB00734 | adrenoceptor alpha 2A | approved; investigational | Risperidone | ||
DB00751 | adrenoceptor alpha 2A | approved; investigational | Epinastine | ||
DB00797 | adrenoceptor alpha 2A | approved | Tolazoline | ||
DB00800 | adrenoceptor alpha 2A | approved | Fenoldopam | ||
DB00852 | adrenoceptor alpha 2A | approved | Pseudoephedrine | ||
DB00865 | adrenoceptor alpha 2A | illicit; approved | Benzphetamine | ||
DB00925 | adrenoceptor alpha 2A | approved | Phenoxybenzamine | ||
DB00935 | adrenoceptor alpha 2A | approved | Oxymetazoline | ||
DB00964 | adrenoceptor alpha 2A | approved | Apraclonidine | ||
DB00968 | adrenoceptor alpha 2A | approved | Methyldopa | ||
DB01018 | adrenoceptor alpha 2A | approved; investigational | Guanfacine | ||
DB01049 | adrenoceptor alpha 2A | approved | Ergoloid mesylate | ||
DB01142 | adrenoceptor alpha 2A | approved | Doxepin | ||
DB01149 | adrenoceptor alpha 2A | approved; withdrawn | Nefazodone | ||
DB01186 | adrenoceptor alpha 2A | approved; withdrawn | Pergolide | ||
DB01200 | adrenoceptor alpha 2A | approved; investigational | Bromocriptine | ||
DB01224 | adrenoceptor alpha 2A | approved | Quetiapine | ||
DB01238 | adrenoceptor alpha 2A | approved; investigational | Aripiprazole | ||
DB01267 | adrenoceptor alpha 2A | approved | Paliperidone | ||
DB01287 | adrenoceptor alpha 2A | approved | Dihydroergotoxine | ||
DB01392 | adrenoceptor alpha 2A | approved | Yohimbine | ||
DB01403 | adrenoceptor alpha 2A | approved | Methotrimeprazine | ||
DB01472 | adrenoceptor alpha 2A | illicit; experimental | 4-Methoxyamphetamine | ||
DB01577 | adrenoceptor alpha 2A | illicit; approved | Methamphetamine | ||
DB01608 | adrenoceptor alpha 2A | approved | Propericiazine | ||
DB01624 | adrenoceptor alpha 2A | approved | Zuclopenthixol | ||
DB04948 | adrenoceptor alpha 2A | approved; investigational | Lofexidine | ||
DB06148 | adrenoceptor alpha 2A | approved | Mianserin | ||
DB06262 | adrenoceptor alpha 2A | approved; investigational | Droxidopa | ||
DB06694 | adrenoceptor alpha 2A | approved | Xylometazoline | ||
DB06711 | adrenoceptor alpha 2A | approved | Naphazoline | ||
DB01105 | adrenoceptor alpha 2A | illicit; approved; withdrawn; investigational | Sibutramine | ||
DB00422 | adrenoceptor alpha 2A | approved; investigational | Methylphenidate |
Top |
Cross referenced IDs for ADRA2A |
* We obtained these cross-references from Uniprot database. It covers 150 different DBs, 18 categories. http://www.uniprot.org/help/cross_references_section |
Copyright © 2016-Present - The Univsersity of Texas Health Science Center at Houston @ |